NEW YORK, April 5 (Reuters) - The U.S. Treasury Department's proposed new tax regulations threw a series of corporate mergers into question on Tuesday, fanning a hot political situation and pushing Pfizer Inc closer to a decision to walk away from buying Botox maker Allergan Plc.
